Pharmacy Focus: Psychedelic Pharmacy - Ibogaine Offers Unique Benefits

Commentary
Podcast

Although it has some daunting adverse effects, Glenn Short, PhD, said ibogaine offers unique biological and therapeutic effects.

This month, we spoke with Glenn Short, PhD, senior vice president of Early Development at atai Life Sciences, about an under-discussed psychedelic drug: ibogaine. Although it has some daunting adverse effects, Short said ibogaine offers unique biological and therapeutic effects.

Related Videos
Credit: Adobe Stock - Tierney
https://www.youtube.com/watch?v=Q-WCvWaAcC8
Yaruniv-Studio - stock.adobe.com
Technician- © pharmacytimes
Pills on a background of a one hundred American dollar bill | Image credit: Cagkan - stock.adobe.com
Credit: Cagkan - stock.adobe.com
Specialty pharmacy illustration | Image credit: BillionPhotos.com - stock.adobe.com
Related Content

MDMA-Assisted Therapy Demonstrates Significant Reductions in Post-Traumatic Stress Disorder Symptoms in Phase 3 Study

September 15th 2023

Pharmacy Focus: Psychedelic Pharmacy - Digital Therapeutics in Psychedelic Medicine

July 14th 2023

Patients With Cancer Using Nonmedical Stimulants Can Continue Using Opioids, Regardless of Prognosis

September 13th 2023

Pharmacy Focus: Oncology Edition - A Look Into Psychedelic Medicines for Oncology Care

June 26th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

California Bill to Decriminalize Natural Psychedelics Passes State Legislature on the Heels of Phase 2 Data Showing Safety, Efficacy of Psilocybin for MDD

September 11th 2023

MDMA-Assisted Therapy Demonstrates Significant Reductions in Post-Traumatic Stress Disorder Symptoms in Phase 3 Study

September 15th 2023

Pharmacy Focus: Psychedelic Pharmacy - Digital Therapeutics in Psychedelic Medicine

July 14th 2023

Patients With Cancer Using Nonmedical Stimulants Can Continue Using Opioids, Regardless of Prognosis

September 13th 2023

Pharmacy Focus: Oncology Edition - A Look Into Psychedelic Medicines for Oncology Care

June 26th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

California Bill to Decriminalize Natural Psychedelics Passes State Legislature on the Heels of Phase 2 Data Showing Safety, Efficacy of Psilocybin for MDD

September 11th 2023

MDMA-Assisted Therapy Demonstrates Significant Reductions in Post-Traumatic Stress Disorder Symptoms in Phase 3 Study

September 15th 2023

Pharmacy Focus: Psychedelic Pharmacy - Digital Therapeutics in Psychedelic Medicine

July 14th 2023

Patients With Cancer Using Nonmedical Stimulants Can Continue Using Opioids, Regardless of Prognosis

September 13th 2023

Pharmacy Focus: Oncology Edition - A Look Into Psychedelic Medicines for Oncology Care

June 26th 2023

Phase 3 Trial Shows Combined Nivolumab, Ipilimumab Treatment Improved OS in Patients With mNSCLC

September 12th 2023

California Bill to Decriminalize Natural Psychedelics Passes State Legislature on the Heels of Phase 2 Data Showing Safety, Efficacy of Psilocybin for MDD

September 11th 2023
© 2023 MJH Life Sciences

All rights reserved.